Congress did not include an extension of the current Medicare reimbursement rates for DXA in the Middle Class Tax Relief and Job Creation Act, H.R. 3630. Despite a strong advocacy effort carried out by NOF and the DXA Coalition in contacting Members of Congress, as well as strong bipartisan support among many of the House and Senate conferees who negotiated the tax package, there was some opposition to extending the current Medicare reimbursement rates for DXA, resulting in the provisions being eliminated from the final package.
A new study published this week in the December issue of Health Affairs looked at the impact cuts in Medicare Part B reimbursement have had on access and utilization of DXA testing, the imaging procedure accepted as the gold standard for diagnosing osteoporosis. The study found that after a decade of growth, DXA testing in all Part B settings was stagnant from 2007-2009, resulting in 800,000 fewer tests than expected for Medicare beneficiaries, which if conducted, may have prevented approximately 12,000 fractures.
ORAL REMARKS – NOF President Robert R. Recker - FDA – September 9, 2011
Good afternoon. I am Dr. Robert Recker, director of the Osteoporosis Research Center at Creighton University in Omaha, Nebraska and am here as president of the National Osteoporosis Foundation, the leading consumer and community-focused health organization dedicated to the prevention of osteoporosis and broken bones.
In this letter, NOF President, Dr. Robert R. Recker, commends the FDA for examining the benefits and risks of long term bisphosphonate use and lays out NOF’s hope that its recommendations will help patients and their healthcare providers better understand the benefits and significant risks of the widely prescribed medications.
As the administration works to implement the Affordable Care Act, there are several regulatory proposals on the horizon. NOF highlighted the need for osteoporosis care for men and women after they have broken a bone in its comments on one such proposal which would affect access to quality care for Medicare patients.
WASHINGTON, D.C., (June 9, 2011) — In an effort to protect patient access to osteoporosis testing and reduce the physical and economic burden of osteoporosis for millions of Americans, Senators Olympia Snowe (R-ME) and Debbie Stabenow (D-MI) and Representatives Michael Burgess (R-26-TX) and Shelley Berkley (D-1-NV) introduced in Congress the “Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011” (S. 1096 and H.R. 2020).
On May 26, 2011, the National Osteoporosis Foundation (NOF), along with 22 other patient, professional, health and community organizations sent a letter to Senators Snowe and Stabenow, and Representatives Burgess and Berkley, thanking them for introducing S. 1096/H.R. 2020.
Download the House letter.
Download the Senate letter.
WASHINGTON — On Thursday, May 12, Senator Kirsten E. Gillibrand of New York introduced in the Senate the “Bone Health Promotion and Research Act of 2011” (S.
Washington, DC - May 3, 2011 - To launch National Osteoporosis Awareness and Prevention Month on Capitol Hill, NOF hosted a congressional briefing on May 3, 2011. Congressional staff heard from a patient, a caregiver, and health professionals about the importance of strong bones to overall health.



Congress currently is deliberating the federal budget for Fiscal Year 2011, which in turn affects funding for federal agencies. The National Institutes of Health (NIH), the federal government’s premier biomedical research agency that conducts research on areas that include osteoporosis and bone health, does not have its funding for all of Fiscal Year 2011 (Oct. 1, 2010 – Sept. 30, 2011) and may face continuing budget cuts. Reducing NIH’s funding could result in setbacks in osteoporosis and bone health research.